Table 2. Licensed Meningococcal Conjugate Vaccine Products.

Vaccine	Manufacturer	Serogroups	Protein Conjugate	Licensed schedule	References
MenveoTM	Novartis Vaccines	A, C, Y, W	Diphtheria cross	In US, one dose at the age of 2 years. 2nd dose 2 months after 1st dose in high-risk children aged 2–5 years	14,15
			Reactive material 197 (CRM197)	In Europe, approved for use from 2 months of age
MenactraTM	Sanofi Pasteur	A, C, Y, W	Diphtheria toxoid	1st dose in children aged 9–23 months. 2nd dose after 3 months in the age 2–55 years.	16–18
MeningitecTM	Neuron Biotech	C	CRM197	4 doses for children <1 year at 2, 4, 6, and 12 months. One dose for children over 12 months, teenagers and adults	19
Menjugate®	Novartis Vaccines	C	CRM197	Age 2–4 months – 3 doses 8 weeks apart, 4–11 months – 2 doses 8 weeks apart, ≧12 months – 1 dose	20,21
NeisVac-CTM	Baxter Bioscience	C	Tetanus toxoid	Age 2–12 months – 2 doses 2 months apart. ≥12 months – 1 dose	22
MenitorixTM	GlaxoSmithKline	C	Tetanus toxoid	Age 2–12 months – 3 doses, 1 month apart. Booster from 12 months – 2 years	23,24
MenAfriVacTM	Serum Institute of India	A	Tetanus toxoid	To be defined	24,25
MenHibrixTM	GlaxoSmithKline	C & Y	Tetanus toxoid	Age 2–15 months – four doses	26